News
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...
The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...
16h
Investor's Business Daily on MSNSarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...
21h
Stocktwits on MSNThis Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...
The Trump administration’s decision to cut nearly $500 million in federal support for the development of mRNA vaccines is ...
AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...
Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.
Crypto Remains in the Spotlight: Investors continue to buy all things crypto. Bullish (BLSH) went public in an IPO yesterday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results